Skip to content
Navigate to the Corvia Medical website home page Corvia Medical Navigate to the Corvia Medical website home page
  • Find a Center
  • Safety Info
  • Newsroom
    • Press Releases
    • Media Resources
    • In the News
  • Contact
  • International
    • US
  • Corvia Atrial Shunt System
  • Patients
  • Healthcare Professionals
    • Dynamic Decompression
    • Clinical Evidence Summary
    • Clinical Program
    • RESPONDER-HF
    • Patient Identification & Referral
    • Reimbursement
    • Presentations, Abstracts, Publications
  • About Us
    • Leadership
    • Board of Directors
    • Investors
    • Patents
  • Find a Center
  • Safety Info
  • Newsroom
    • Press Releases
    • Media Resources
    • In the News
  • Contact
  • US
  • Corvia Atrial Shunt System
  • Patients
    • Learn About Heart Failure
    • Learn About Atrial Shunting
    • Heart Failure Symptom Check
    • Find A Doctor
  • Healthcare Professionals
    • Dynamic Decompression
    • Clinical Evidence Summary
    • Clinical Program
    • RESPONDER-HF
    • Patient Identification & Referral
    • Corvia Atrial Shunt Responders
    • Reimbursement
    • Presentations, Abstracts, Publications
  • About Us
    • Leadership
    • Board of Directors
    • Investors
    • Patents
Newsroom

Press Releases

  • December 20 2024
    Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards
  • October 25 2024
    Corvia Medical Announces Three-Year Clinical Trial Results Confirming Significant and Durable Benefits of the Corvia Atrial Shunt in Heart Failure Patients
  • August 19 2024
    Corvia Medical’s Groundbreaking Study Affirms Long-Term Benefits of the Corvia Atrial Shunt for Heart Failure Patients
  • May 7 2024
    Newly Published Data in JAMA Cardiology Demonstrates Favorable Long-term Effects of the Corvia Atrial Shunt in Heart Failure Patients 
  • April 12 2024
    Corvia’s RESPONDER-HF Confirmatory Trial Supported by RELIEVE-HF Data
  • May 22 2023
    Corvia Medical Releases Two-Year Clinical Trial Results Confirming Sustained Benefit and Safety of its Atrial Shunt in Heart Failure Patients
  • December 6 2022
    Corvia Medical Announces Randomization of First Patient in the RESPONDER-HF Confirmatory Trial
  • June 9 2022
    Corvia Medical Closes $54 Million Financing To Support Planned Confirmatory Trial Of The Corvia® Atrial Shunt
  • April 1 2022
    REDUCE LAP-HF II Analyses show 50% of study patients demonstrated significant Clinical Benefit from the Corvia® Atrial Shunt
  • February 1 2022
    Landmark REDUCE LAP-HF II Trial Demonstrates Clinical Benefit of Corvia® Atrial Shunt in Large Segment of Heart Failure Patients
  • November 17 2020
    Corvia Medical Completes Randomization in REDUCE LAP-HF II Pivotal Trial and Gains FDA Authorization to Provide Continued Access for the Corvia Atrial Shunt
  • January 13 2020
    First Japanese Patients Randomized in Corvia Medical’s REDUCE LAP-HF II Global Clinical Trial for Heart Failure
  • October 9 2019
    Corvia Medical’s Interatrial Shunt Device (IASD®) Receives Breakthrough Device Designation For Heart Failure
  • March 11 2019
    Corvia Medical Enters Into Agreement With Edwards Lifesciences, The Global Leader In Structural Heart Innovation
  • August 27 2018
    Corvia Medical Announces Strong Positive One-Year Data From Reduce Lap-Hf I Randomized, Sham-Controlled Clinical Trial
  • November 14 2017
    Corvia Medical Announces Enrollment of First Patients in Pivotal Trial of the IASD® System II for the Treatment of Heart Failure
  • November 16 2016
    Corvia Medical Announces Strong Positive One-Year Data from Reduce LAP-HF Clinical Study
  • May 12 2016
    Corvia Medical Announces CE Mark Approval and Enrollment of First Patients in Randomized Clinical Study
  • March 7 2016
    Corvia Medical Receives IDE Approval for REDUCE LAP-HF I Clinical Study & Announces Agreement with Strategic Partner for Exclusive Option to Purchase Company
  • June 22 2015
    DC Devices Completes Enrollment In Clinical Trial of the First Transcatheter Device to Treat Diastolic Heart Failure; Announces Name Change to Corvia Medical
  • July 1 2014
    DC Devices Closes $34m Series D Financing to Complete Clinical Evaluation of the First Transcatheter Device to Treat Diastolic Heart Failure
  • March 15 2013
    DC Devices Secures $9 Million Financing; Lumira Capital Joins Syndicate of Leading Investors
  • Press Releases
  • Media Resources
  • In the News

Corvia Medical, Inc.

One Highwood Drive, Suite 300
Tewksbury, MA 01876
USA

+1 978-654-6123
info@corviamedical.com

The Corvia Atrial Shunt System (IASD®)

is indicated for the improvement in quality of life and reduction of heart failure related symptoms and events in patients with heart failure with preserved (HFpEF) or mid-range ejection fraction (HFmrEF) with elevated left atrial pressures, who remain symptomatic despite standard guideline directed medical therapy.

© 2025 Corvia Medical. All rights reserved. Privacy Policy

Corvia and IASD are registered trademarks of Corvia Medical, Inc.

CAUTION–Investigational Device. Limited by United States Law to Investigational Use.

I understand

Manage Cookie Consent
We use cookies to optimize our website and our service.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
Preferences
{title} {title} {title}